A randomized, controlled,14-treatment day, multicenter study to determine the optimal efficacious and safe dose of CHF 4226 in a metered dose inhaler in treating patients with chronic obstructive pulmonary disease.

Trial Profile

A randomized, controlled,14-treatment day, multicenter study to determine the optimal efficacious and safe dose of CHF 4226 in a metered dose inhaler in treating patients with chronic obstructive pulmonary disease.

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Apr 2017

At a glance

  • Drugs Carmoterol (Primary) ; Salmeterol
  • Indications Chronic obstructive pulmonary disease
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 12 Jul 2011 New source identified and integrated (European Clinical Trials Database, EudraCT2006-000531-10 ).
    • 12 Jul 2011 New source identified and integrated (European Clinical Trials Database, EudraCT2006-000531-10 ).
    • 10 Mar 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top